Dronabinol · Marinol, Syndros

What is Dronabinol?

Dronabinol is an orally active cannabinoid that binds to cannabinoid receptors in the central nervous system. It acts on appetite and vomiting control centers in the brain to stimulate appetite and prevent nausea and vomiting.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Marinol, Syndros, SP-104, ABBOTT-40566, J882F

Drug type

Small molecule

Targets

cannabinoid receptor (CNR1)

Mechanism

Agonist of cannabinoid receptor (CNR1)

Pathways

appetite stimulation, emesis prevention

Therapy area

Infectious disease, Oncology

Developer

Alkem Labs Ltd

In trials of

SCLX

FDA status

Approved as Marinol, Syndros (May 31, 1985), NDA018651 · FDA label

UNII

7J8897W37S

✅ FDA-approved uses

• Anorexia associated with weight loss in patients with AIDS (Marinol)
• Nausea and vomiting associated with cancer chemotherapy (Marinol)
• Anorexia associated with weight loss in patients with AIDS (Syndros)
• Nausea and vomiting associated with cancer chemotherapy (Syndros)

From the indications section of the FDA label (version of Feb 14, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Other drugs acting on CNR1

Sources

• FDA label (DailyMed)
• FDA label Dronabinol (2026-05-13), indications
• FDA label Syndros (2026-04-21), indications
• FDA label Marinol (2023-02-14), indications
• NCI Thesaurus

Updated Oct 3, 2026.